Interesting poll at Forbes

What's Your Take On Drug Advertising To Consumers?
12.20.04, 8:00 AM ET

The U.S. Food and Drug Administration is considering further regulatory measures, including withdrawal from the market, of Pfizer's arthritis treatment Celebrex. The recent FDA attention is in response to a study by the National Cancer Institute showing that high doses of Celebrex--a Cox-2 inhibitor similar to Merck's recalled drug Vioxx--were associated with an increased risk of heart attack and stroke (see: "Pfizer's Heart Attack").

Yesterday, New York-based Pfizer (nyse: PFE - news - people ) announced it would immediately halt TV, radio, newspaper and magazine ad campaigns promoting Celebrex to U.S. consumers. The drugmaker spent more than $70 million on such advertising in the first nine months of 2004. Pfizer will continue to market Celebrex, which has annual sales of $3 billion, to doctors.

Do you think that it's appropriate to advertise prescription drugs to consumers?

Vote Here